Cariprazine for depression in bipolarity
About this title
Safety and Efficacy of RGH-188 (Cariprazine) in Bipolar Depression
Read the official source — NCT00852202Researchers compared cariprazine and placebo to find out how the approaches affected depression symptoms in people with bipolarity during a depressive episode.
Understand this study
What did researchers investigate?
Researchers compared cariprazine and placebo to find out how the approaches affected depression symptoms in people with bipolarity during a depressive episode.
Who was this study for?
This study was for people with bipolarity. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
- Listed locations
- Encino and 25 more locationsSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
- Recruitment status
- Completed
- Enrollment listed in the registry
- 234
- Sponsor
- Forest Laboratories
- Sponsor type
- Pharmaceutical company
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT00852202
- Official title
Show the full official title
A Double-blind, Placebo-controlled Study of RGH-188 (Cariprazine) in Bipolar Depression
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
Encino · Garden Grove · National City
23 more locations
- Newport Beach
- Oceanside
- Bradenton
- Jacksonville
- Kissimmee
- Orlando
- West Palm Beach
- Glen Burnie
- Creve Coeur
- Omaha
- Cherry Hill
- The Bronx
- Durham
- Dayton
- Mason
- Portland
- Media
- Philadelphia
- Nashville
- Irving
- Woodstock
- Bellevue
- Seattle
Interested in joining this study?
Questions about this study
What did researchers investigate?
Researchers compared cariprazine and placebo to find out how the approaches affected depression symptoms in people with bipolarity during a depressive episode.
Who is behind this study?
The study sponsor is Forest Laboratories, a pharmaceutical company.
Did this study involve medication?
Yes. The study involved medication, including cariprazine and placebo.
Who was this study for?
This study was for people with bipolarity. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
